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of Drug-Eluting and Bare-Metal Stents
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Dennis T. Ko, MD, MSC,*† Maria Chiu, MSC,† Helen Guo, MSC,† Peter C. Austin, PHD,†
Ron Goeree, MA,‡ Eric Cohen, MD,* Marino Labinaz, MD,§ Jack V. Tu, MD, PHD*†
Toronto, Hamilton, and Ottawa, Ontario, Canada
Objectives Our main objective was to evaluate the longer-term safety and efficacy of drug-eluting stents (DES) in off-label
indications as compared with bare-metal stents (BMS).
Background DES are frequently implanted in patients with off-label indications. However, the longer-term safety and effec-
tiveness of DES among patients with off-label indications are not well understood.
Methods Propensity score matching analysis was performed in a population-based cohort that included 6,944 off-label
and 9,126 on-label patients who received percutaneous coronary interventions (PCIs) in Ontario, Canada, be-
tween December 1, 2003, and March 31, 2006. Off-label indications were defined on the basis of clinical and
procedural characteristics.
Results For patients with off-label indications, rates of repeat target vessel revascularization at 3 years were significantly
lower among patients treated with DES compared with those treated with BMS (11.6% vs. 15.3%, p  0.001).
Myocardial infarction rates were not significantly different between patients treated with DES and BMS (p 
0.52). Mortality rates were significantly lower among off-label patients treated with DES compared with BMS at
3 years of follow-up (6.9% vs. 10.5%, p  0.001). For patients with on-label indications, the use of DES was as-
sociated with significantly lower rates of target vessel revascularization, but composite rates of myocardial in-
farction or death were not significantly different from BMS.
Conclusions For patients with off-label indications, DES implantation was associated with lower target vessel revasculariza-
tion without an associated increase in longer-term risk of myocardial infarction or death compared with
BMS. (J Am Coll Cardiol 2009;53:1773–82) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.059s
o
(
D
t
i
(
o
d
F
o
A
t
n
y
a
u
crug-eluting stents (DES) have been demonstrated to be
ighly effective in reducing the need for future coronary
evascularization (1–3). Although some early reports have
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008, accepted January 6, 2009.uggested that patients receiving DES may have higher rates
f stent thrombosis, myocardial infarction, or even death
4–8), subsequent evaluations have confirmed the safety of
ES for patients with “on-label” indications, namely pa-
ient subsets that have been enrolled by trials with procedure
ndications approved by the Food and Drug Administration
FDA) (9–11). In contrast, DES use in patients with
ff-label indications, generally defined as clinical or proce-
ure characteristics that have not been approved by the
DA, is associated with substantially higher risk of adverse
utcomes as compared with on-label use of DES (12,13).
lthough a recent study by Marroquin et al. (14) suggests
hat the outcomes associated with off-label use of DES did
ot differ significantly with bare-metal stents (BMS) at 1
ear, residual concerns persist due to the possibility that
dverse outcomes associated with DES may not be apparent
ntil after a year (7). Furthermore, the study compared a
ontemporary DES cohort with a historical cohort of
atients treated with BMS, raising the possibility that the
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Safety of DES for Off-Label Indications May 12, 2009:1773–82outcomes of the contemporary
DES group might have benefit-
ted from improvement in drug
therapy and angioplasty proce-
dure techniques (14).
Since DES are commonly im-
planted among patients with off-
label indications, addressing this
knowledge gap could have a sub-
stantial impact on the practice of
interventional cardiology. The
availability of a large population-
based percutaneous coronary in-
tervention (PCI) database with
linkages to ongoing administra-
ive data afforded a unique opportunity to compare patients
ith off-label indications treated with DES and BMS in a
oncurrent time frame with longer-term follow-up. Accord-
ngly, the main objective of our study was to evaluate the
onger-term safety and effectiveness of DES versus BMS in
atients with off-label indications.
ethods
ata sources. The Ontario PCI database has been previ-
usly described (15). Briefly, the Cardiac Care Network
CCN) of Ontario maintains a prospective clinical registry
f all patients undergoing cardiac catheterization, PCI, and
oronary artery bypass grafting surgery in Ontario, Canada.
urse coordinators at each cardiac invasive center gather
ata on demographics, clinical characteristics, procedure
haracteristics, and relevant comorbid conditions. Since
003, mandatory fields have included the number of stents,
haracteristics of each stent, and location of stent placement
15). For the study, the CCN database was linked to the
anadian Institute for Health Information hospital discharge
bstract database to identify additional comorbid conditions,
he Ontario Diabetes Database to confirm diabetes status, and
tatistics Canada Census data to determine socioeconomic
tatus. Linkages with these various administrative databases
ere performed using unique encrypted patient identifiers to
rotect patient confidentiality.
This study was approved by the Research Ethics Board at
he Sunnybrook Health Sciences Center. The need for
nformed patient consent was waived, as the CCN database
s a prescribed registry under Ontario’s health information
rivacy legislation.
tudy sample. We identified a cohort of patients who
eceived PCI in Ontario from December 1, 2003, to March
1, 2006, which included an additional year of PCI patients
ompared to our previous cohort (15). This time frame was
hosen to allow at least 1 year of follow-up to examine
onger-term outcomes. From this initial cohort, we excluded
atients who had both DES and BMS during the index
CI, patients with severe comorbidities (e.g., dementia,
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CCN  Cardiac Care
Network
DES  drug-eluting stent(s)
FDA  Food and Drug
Administration
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarctionetastatic cancer, severe liver disease) because of competing misks of death, and patients who had an invalid Ontario health
ard number because we could not determine their longer-term
utcomes. Patients who had missing information on important
rognostic factors such as socioeconomic status (n  1,027),
anadian Cardiovascular Society angina classification (n 
22 for missing, n 1,579 for unknown), and stent type (n
22) were also excluded because of our inability to use their
ropensity scores for matching.
efinitions. The off-label cohort was defined using both
linical and procedural characteristics. For clinical characteris-
ics, we considered off-label indications as patients who pre-
ented with cardiogenic shock. We also considered PCI on the
ame day as hospitalization for myocardial infarction as an
ff-label indication. For procedural characteristics, we consid-
red off-label indications as patients who had multivessel
tenting; stent location in the left main artery, in a restenotic
esion, or in the bypass graft; total stent length 33 mm; or
tent diameter (sirolimus-eluting stent 2.5 or 3.5 mm,
aclitaxel-eluting stent 2.5 or 3.75 mm, BMS 2.5 or
3.5 mm) (16,17).
Because previous studies varied in their definitions of
ff-label indications (12–14), we also created an additional
ff-label cohort to examine the robustness of our results. We
eanalyzed our data defining a more restrictive off-label
ohort using only procedure characteristics (stent location,
tent length, and stent size) similar to previous studies
12–14). Our results did not change materially compared
ith the original definition.
utcomes. The primary effectiveness outcome of our study
as repeat target vessel revascularization. The primary
afety outcomes were myocardial infarction and all-cause
ortality. Target vessel revascularization was determined
sing information from the CCN database; myocardial
nfarction was assessed using the Canadian Institute for
ealth Information hospital discharge abstract database
International Classification of Diseases, 10th Revision,
isease codes: I21 and I22) (18); and mortality was deter-
ined from the Ontario Registered Persons Database.
hese outcomes were assessed through March 31, 2007,
ith complete follow-up data for each outcome.
tatistical analysis. Propensity score matching analysis was
sed to account for potential confounding and selection
iases (15,19,20). The predicted probability of DES use was
alculated by fitting a logistic regression model using all of
he clinically relevant variables shown in Table 1. A greedy,
earest neighbor 1:1 matching algorithm was used to match
ubjects based on the logit of the propensity score with
alipers width of 0.2 standard deviations of the logit of the
ropensity score (19,20). Standardized differences of the
ean 0.1 were taken to indicate good balance in the
atched sample (19,20). Patients were used only in 1
ropensity score-matched pair, and those without a suitable
atch were excluded from the analysis.
We first stratified our study sample according to off- and
n-label indications and subsequently performed propensity
atching within each subgroup. Matching within each
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m
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Table 1 Baseline Characteristics of the Propensity Matched Study Cohort*
On-Label Use Off-Label Use
BMS DES BMS DES
Patients, n 4,563 4,563 3,472 3,472
Demographics
Mean age (yrs)  SD 62.3 11.9 62.0 11.5 63.2 12.3 63.2 11.8
65–74 1,178 (25.8%) 1,216 (26.6%) 899 (25.9%) 924 (26.6%)
75–84 720 (15.8%) 674 (14.8%) 623 (17.9%) 600 (17.3%)
85 78 (1.7%) 49 (1.1%) 94 (2.7%) 75 (2.2%)
Male 3,155 (69.1%) 3,183 (69.8%) 2,491 (71.7%) 2,484 (71.5%)
Admission characteristics
Recent AMI (same day as PCI) 0 0 824 (23.7%) 812 (23.4%)
Recent AMI (days 1 to 7) 1,074 (23.5%) 1,082 (23.7%) 567 (16.3%) 585 (16.8%)
Recent AMI (days 7 to 30) 305 (6.7%) 306 (6.7%) 213 (6.1%) 220 (6.3%)
No prior AMI 3,184 (69.8%) 3,175 (69.6%) 1,868 (53.8%) 1,855 (53.4%)
CCS angina class prior to procedure
I 275 (6.0%) 288 (6.3%) 158 (4.6%) 153 (4.4%)
II 828 (18.1%) 807 (17.7%) 459 (13.2%) 467 (13.5%)
III 1,141 (25.0%) 1,149 (25.2%) 688 (19.8%) 705 (20.3%)
IV 1,983 (43.5%) 1,988 (43.6%) 1,856 (53.5%) 1,864 (53.7%)
Cardiogenic shock 0 0 95 (2.7%) 80 (2.3%)
Cardiac risk factors and comorbidities
Hypertension 1,779 (39.0%) 1,776 (38.9%) 1,354 (39.0%) 1,409 (40.6%)
Diabetes 1,406 (30.8%) 1,426 (31.3%) 1,122 (32.3%) 1,116 (32.1%)
Prior coronary artery bypass grafting 261 (5.7%) 263 (5.8%) 500 (14.4%) 500 (14.4%)
Prior PCI 286 (6.3%) 280 (6.1%) 220 (6.3%) 246 (7.1%)
Prior stroke or transient ischemic attack 117 (2.6%) 123 (2.7%) 118 (3.4%) 112 (3.2%)
Chronic obstructive pulmonary disease 217 (4.8%) 206 (4.5%) 168 (4.8%) 155 (4.5%)
Heart failure 216 (4.7%) 213 (4.7%) 210 (6.0%) 188 (5.4%)
Peripheral vascular disease 271 (5.9%) 257 (5.6%) 260 (7.5%) 255 (7.3%)
Cancer 50 (1.1%) 43 (0.9%) 33 (1.0%) 33 (1.0%)
Hemodialysis 42 (0.9%) 51 (1.1%) 43 (1.2%) 42 (1.2%)
Socioeconomic status
I 865 (19.0%) 885 (19.4%) 670 (19.3%) 642 (18.5%)
II 930 (20.4%) 950 (20.8%) 692 (19.9%) 728 (21.0%)
III 945 (20.7%) 931 (20.4%) 699 (20.1%) 712 (20.5%)
IV 932 (20.4%) 921 (20.2%) 705 (20.3%) 710 (20.4%)
V 891 (19.5%) 876 (19.2%) 706 (20.3%) 680 (19.6%)
Procedural characteristics
Stent location
Left main 0 0 108 (3.1%) 116 (3.3%)
Left anterior descending 2,188 (48.0%) 2,176 (47.7%) 1,622 (46.7%) 1,601 (46.1%)
Left circumflex 1,052 (23.1%) 1,063 (23.3%) 1,131 (32.6%) 1,083 (31.2%)
Right coronary artery 1,323 (29.0%) 1,324 (29.0%) 1,341 (38.6%) 1,346 (38.8%)
Bypass graft (vein or arterial graft) 0 0 301 (8.7%) 294 (8.5%)
Multiple vessel stenting 0 0 986 (28.4%) 933 (26.9%)
Stent for restenosis 0 0 55 (1.6%) 76 (2.2%)
Stent characteristics, mean  SD
No. of stented vessels 1.00 0.00 1.00 0.00 1.30 0.50 1.28 0.48
No. of stents 1.11 0.32 1.11 0.32 2.01 1.00 2.00 0.98
Stent diameter 2.94 0.32 2.94 0.33 2.86 0.46 2.87 0.41
Stent length 19.0 6.1 19.0 6.2 36.8 21.0 36.7 18.6
ll values are presented as n (%) unless otherwise specified. *Off-label indications include cardiogenic shock; percutaneous coronary intervention (PCI) same day as acute myocardial infarction (AMI);
ultivessel stenting; stent location in the left main artery, in a restenotic lesion, or in the bypass graft; total stent length 33 mm; or stent diameter (sirolimus-eluting stent 2.5 or 3.5 mm,
aclitaxel-eluting stent 2.5 or 3.75 mm, bare-metal stent [BMS] 2.5 or 3.5 mm).
CCS  Canadian Cardiovascular Society; DES  drug-eluting stent.
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Safety of DES for Off-Label Indications May 12, 2009:1773–82ubgroup allowed the creation of a matched sample of DES
nd BMS patients within each subgroup who had a similar
istribution of demographics, clinical, and procedure char-
cteristics. However, the characteristics across the off- and
n-label indications were not matched, and outcomes should
ot be compared across these subgroups (19,20). The distri-
ution of categorical variables, distribution of continuous
ariables, and survival curves were compared using appropriate
tatistical methods for matched data. We reported p values that
ompared the Kaplan-Meier survival curves for each outcome
ver the entire follow-up period. Due to the matched-pair
ature of our data, calculating p values comparing outcomes at
pecific points in time was not possible (19,20).
Sensitivity analyses were performed on the unmatched
ohort of patients who met study eligibility using multivar-
ate Cox proportional hazards regression adjusting for clin-
cally relevant characteristics listed in Table 1. Subgroup
nalyses of patients with myocardial infarction (same day as
CI), multiple vessel stenting, and diabetes were also per-
ormed using regression techniques.
SAS version 9.l (SAS Institute, Cary, North Carolina)
as used for statistical analyses. A 2-sided p value of 0.05
linical Outcomes After Index PCI Among On- and Off-Label Patient
Table 2 Clinical Outcomes After Index PCI Among On- and Off-L
On-Label Use
Outcomes* BMS (n  4,563) DES (n  4,56
Target vessel revascularization (%)
6 months 4.2 2.5
1 yr 6.7 4.3
1.5 yrs 7.9 5.5
2 yrs 8.8 6.3
2.5 yrs 9.4 7.1
3 yrs 10.3 8.0
Myocardial infarction (%)
6 months 1.1 0.8
1 yr 1.7 1.4
1.5 yrs 2.4 2.4
2 yrs 3.0 3.2
2.5 yrs 3.5 4.0
3 yrs 3.9 4.7
Death (%)
6 months 2.0 1.3
1 yr 2.9 1.8
1.5 yrs 3.7 2.8
2 yrs 4.8 3.4
2.5 yrs 5.7 4.0
3 yrs 6.6 5.2
Myocardial infarction or death (%)
6 months 3.0 2.0
1 yr 4.4 3.1
1.5 yrs 5.8 4.9
2 yrs 7.4 6.2
2.5 yrs 8.5 7.6
3 yrs 9.7 9.3Outcome rates were derived from paired Kaplan-Meier curves; †p values were calculated by comparing
Abbreviations as in Table 1.as considered statistically significant in the comparison
f outcomes.
esults
tudy sample. After inclusion and exclusion criteria were
pplied, our cohort included 14,916 patients who had
n-label indications and 14,088 patients who had at least 1
ff-label indication. After applying propensity score match-
ng and excluding patients without a suitable match, our
ain analysis included 4,563 matched pairs of patients (n
,126) with on-label indications and 3,472 matched pairs of
atients (n  6,944) with off-label indications.
In the off-label group, the mean age was 63 years, 32%
ad diabetes, and 23% had an acute myocardial infarction
n the same day as the index PCI (Table 1). Stents were
laced most commonly (46%) in the left anterior descending
rtery, mean stent length was 37 mm, and mean stent
iameter was 2.9 mm.
All demographics, clinical, and procedural characteristics
ere well balanced in the matched pairs of DES and BMS
atients. None of the admission or procedure characteristics
ad standardized difference of the means exceeding 0.1,
Patients
Off-Label Use
p Value† BMS (n  3,472) DES (n  3,472) p Value†
0.001 0.001
7.6 3.8
10.7 6.1
12.3 7.7
12.9 9.0
14.0 10.1
15.3 11.6
0.43 0.52
2.0 1.8
2.7 2.7
3.4 3.4
3.9 4.7
4.1 5.6
5.3 6.9
0.0075 0.001
5.3 2.6
6.5 3.7
7.3 4.9
8.5 5.8
9.8 6.5
10.5 6.9
0.089 0.0016
7.0 4.2
8.7 6.0
10.1 7.5
11.5 9.5
12.8 11.1
14.7 12.6s
abel
3)the paired Kaplan-Meier curves.
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May 12, 2009:1773–82 Safety of DES for Off-Label Indicationsndicating the creation of a well-balanced propensity
atched cohort for the off-label group (Table 1). Similarly,
atients with on-label indications were also well matched
etween the DES and BMS groups in terms of demograph-
cs, admission characteristics, and clinical characteristics
fter propensity score matching (Table 1).
arget vessel revascularization. Overall, DES use was
ssociated with a reduction in target vessel revascularization
fter the index PCI. Among patients with off-label indica-
ions, target vessel revascularization rates were 11.6% for
atients who received a DES and 15.3% for those who
eceived a BMS at 3-year follow-up (p  0.001) (Table 2,
ig. 1A). A significant reduction in the rates of target vessel
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Figure 1 TVR in Off-Label Patients
Target vessel revascularization (TVR) in the propensity score-matched cohort comp
drug-eluting stents (DES) and bare-metal stents (BMS) for patients with (A) off-labevascularization was also observed for on-label patients
reated with DES, although the absolute rate of reduction
as slightly smaller (absolute difference of 2.3%; 10.3% in
he BMS group vs. 8.0% in the DES group) at 3-year
ollow-up (Table 2, Fig. 1B).
yocardial infarction and death. For patients with off-
abel indications, the median follow-up duration for
yocardial infarction and death was 2 years, and 11% had
follow-up period of more than 3 years. The rate of
yocardial infarction during the study period did not
iffer significantly between the DES and the BMS groups
or patients with off-label indications (p  0.52)
Fig. 2A). However, myocardial infarction rates of pa-
er Index PCI
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Safety of DES for Off-Label Indications May 12, 2009:1773–82ients treated with DES and BMS appeared to diverge
fter 18 months; the rate was 1.6% higher in the DES
roup by 3 years of follow-up. The use of DES was
ssociated with significantly lower rates of death (3-year
ates: 6.9% for DES, 10.5% for BMS, p  0.001) and the
omposite end point of myocardial infarction or death
3-year rates: 12.6% for DES, 14.7% for BMS, p 
.002) (Table 2, Figs. 3A and 4A).
For patients with on-label indications, the rate of death
as also significantly lower among patients who received a
ES compared with those who received a BMS (3-year
ates: 5.2% for DES, 6.6% for BMS, p  0.008) (Table 2,
ig. 3B). However, rates of myocardial infarction or the
ombined rates of myocardial infarction or death did not
iffer significantly among patients who were treated with
ES as compared with patients treated with BMS (p 
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Figure 2 MI in Off-Label Patients
Myocardial infarction (MI) in the propensity score-matched cohort in DES and BMS
DES and BMS for patients with (A) off-label and (B) on-label indications. Abbrevia.43 for myocardial infarction, p  0.089 for myocardial
nfarction or death) (Table 2, Figs. 2B and 4B).
ensitivity analysis. Results of the sensitivity analysis us-
ng multivariate proportional hazard models of the un-
atched sample of 29,002 patients were similar to those of
he propensity score-matched cohort in which DES were
ssociated with a significant reduction in death and target
essel revascularization without an associated increased risk
f myocardial infarction (Table 3). When DES and BMS
ere compared in subgroups, DES were associated with a
ignificant reduction in death compared with BMS (Table 3).
iscussion
e conducted a comprehensive evaluation of the safety and
fficacy of DES among patients with off-label indications,
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May 12, 2009:1773–82 Safety of DES for Off-Label Indicationsnd determined longer-term outcomes with virtually 100%
ollow-up. Using liberal definitions to create an off-label
ohort that included clinical and procedural characteris-
ics, we found that DES were effective in reducing the
eed for target vessel revascularization without observing
n increased risk of myocardial infarction. More impor-
antly, patients with off-label indications receiving DES
ad lower mortality rates when compared with patients
eceiving BMS. These findings were robust under different
efinitions of off-label indications. Our results should alleviate
ecent concerns and may lend support to the contemporary
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DES are frequently implanted among patients with
ff-label indications and therefore, early studies demonstrat-
ng a higher risk of adverse outcome associated with DES
rought significant concerns in clinical practice (12,13). We
ound that approximately one-half of all patients who
eceived DES had at least 1 off-label indication. This
stimate is consistent with the proportions reported in the
ational Heart, Lung, and Blood Institute Dynamic Reg-
stry (48.7%), the Evaluation of Drug Eluting Stents and
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egistry (47%) (12–14).
The main finding of the paper was the observation that
ortality rates were lower among patients with off-label
ndications treated with DES compared with BMS. Survival
urves among patients with off-label indications continued
o slowly diverge over time, favoring fewer deaths among
atients treated with DES, which may support the potential
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Figure 4 MI or Death in Off-Label Patients
MI or death in the propensity score-matched cohort comparing DES and BMS for
patients with (A) off-label and (B) on-label indications. Abbreviations as in Figureseneficial impact of DES on mortality at longer term in barallel with its ability to reduce repeat revascularization
21). Although randomized trials have not been able to
emonstrate an impact of DES on mortality, the finding of
ower mortality rates associated with DES is concordant
ith a growing body of literature that has suggested that
ES may lower mortality compared with BMS (15,22–24).
evertheless, our study was not randomized and is subject
o unmeasured confounding despite our rigorous attempt to
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May 12, 2009:1773–82 Safety of DES for Off-Label IndicationsWe did not find an overall increased myocardial infarc-
ion rate associated with DES compared with BMS in the
-year follow-up period. However, Kaplan-Meier curves of
ES and BMS appeared to diverge over time, with possibly
ore myocardial infarction events occurring in the DES
roup after 18 months. Since information on stent throm-
osis was not available in our database, we were unable to
ssess whether this trend was due to differences in rates of stent
hrombosis associated with DES. Additional follow-up would
e necessary to examine whether this trend continues to persist
ver time.
With regard to the efficacy of DES, we found that target
essel revascularization was significantly reduced compared
ith BMS among off- and on-label patients. Interestingly,
larger absolute reduction in target vessel revascularization
as observed among patients in the off-label group as
ompared with the on-label group. These findings are
onsistent with the hypothesis that DES are more cost-
ffective when used in patients with higher risk of restenosis
nd also lend support to policies that recommend DES for
atients with longer lesions and smaller vessels, analogous to
ur off-label group.
tudy limitations. First, sirolimus-eluting stents are cur-
ently approved for de novo lesions in native coronary
rteries no longer than 30 mm with reference vessel diam-
ter of at least 2.5 to 3.5 mm (16), and paclitaxel-eluting
tents for lesions no longer than 28 mm with a reference
iameter of at least 2.5 to 3.75 mm (17). Since our data did
ot include specific lesion characteristics, we used stent size
nd length as surrogates for lesion length and vessel size to
efine our off-label cohort. Furthermore, we were unable to
valuate specific lesion subsets, such as ostial, bifurcation, or
otally occluded arteries.
Second, a recent analysis by the Global Registry of Acute
oronary Events suggests that patients with ST-segment
levation myocardial infarction (STEMI) treated with DES
ad a significantly increased rate of death compared with BMS
25). We were unable to determine the safety of DES for
TEMI specifically because this data element was not captured
n our database, although several recent studies have suggested
he safety of DES in STEMI patients in clinical practice
linical Outcomes Associated With the Use of DES in Patientsth Off-Label Indicati ns: Multivariat Cox Proportional Hazards M
Table 3 Clinical Outcomes Associated With the Use of DES inWith Off-Label Indications: Multivariate Cox Proportion
All Off-Label Patients
(n  14,086)
Diabet
(n 
Outcomes HR (95% CI) p Value HR (95% C
Target vessel
revascularization
0.65 (0.57–0.73) 0.001 0.54 (0.44–0
Myocardial infarction 1.17 (0.97–1.41) 0.094 1.13 (0.85–1
Death 0.56 (0.48–0.65) 0.001 0.56 (0.45–0
Myocardial infarction or death 0.74 (0.66–0.84) 0.001 0.71 (0.59–0
See Table 1 and the Methods section for the definition of off-label indications. Each model was
rug-eluting stents (DES). †Percutaneous coronary interventions on the same day as hospitalizati
CI  confidence interval.26,27). Third, we did not examine the impact of evidence-ased medical therapy, such as thienopyridine, as a potential
eason to explain the benefit associated with DES.
Finally, our study should be placed in the context of the PCI
ractice in Ontario, Canada. For example, Ontario has recom-
ended a policy of 1-year clopidogrel coverage since 2003 for
atients undergoing PCI where all patients over age 65 years
re eligible to receive a 1-year supply of clopidogrel (15).
urthermore, the majority of younger patients have private
nsurance coverage for prescribed medications (15).
onclusions
n summary, our study lends support to the contemporary
ractice of implanting DES for patients with off-label
ndications as we found that patients treated with DES had
lower risk of target vessel revascularization and mortality
ompared with those treated with BMS. These findings
hould be confirmed through large, randomized clinical
rials evaluating patients with off-label indications.
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